In a report released today, Ram Selvaraju from H.C. Wainwright initiated coverage with a Buy rating on CytoDyn Inc (CYDY) and a price target of $1.50. The company’s shares closed yesterday at $0.62.
Selvaraju wrote:
“Our price target is derived from an estimated market value of the firm at $495M, which includes a discounted cash flow-based asset value of $500M for PRO 140 in the HIV indication alone, with a 15% discount rate, 2% terminal growth rate, 80% probability of success, and excluding $5M debt.”
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.9% and a 21.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Aerpio Pharmaceuticals Inc.
CytoDyn Inc has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.
See today’s analyst top recommended stocks >>
Based on CytoDyn Inc’s latest earnings release for the quarter ending August 31, the company reported a quarterly GAAP net loss of $14.41 million. In comparison, last year the company had a GAAP net loss of $11.63 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. Its product pipeline includes PRO 140, CytoFeline, and Cytolin.
